Encube Ethicals Limited
DRHP · filed 06 Aug 2026
This is a draft. SEBI has not cleared it, there is no final price yet, and it may never become an IPO.
Encube Ethicals Limited operates in the global generics and contract development and manufacturing organization (CDMO) sectors. The offer consists entirely of an offer for sale of 30,000 equity shares. The company has a debt-to-equity ratio of 0.12. High risks include potential adverse effects from a downturn in demand, price erosion from increased competition, regulatory actions by the USFDA, and the loss of customer orders.
Partial analysis — some sections could not be read from the document (found: capitalisation, litigation, objects, price_basis, promoters, related_party, risks).
What stands out
Mostly an exit. 100% of the offer is an Offer for Sale, so most proceeds go to selling shareholders, not the company.
Risk factor. A downturn or reduction in demand in either the Global Generics or Global CDMO business verticals could adversely affect the business, results of operations, cash flows and financial condition.
Risk factor. Revenue from the Global Generics business vertical may be adversely affected by increased price erosion resulting from a greater number of ANDA approvals for competing generic products.
Risk factor. Revenue from the Global Generics business vertical may be adversely affected by regulatory actions by the USFDA, including Official Action Indicated, warning letters, import alerts or facility-level enforcement actions.
Low leverage. Debt-to-equity of 0.12x.
How the offer is structured
Offer for sale
₹30.00k Cr
Goes to selling shareholders
OFS share
100%
- carry out the Offer for Sale of up to [●] Equity Shares of face value of ₹1 each by the Selling Shareholders aggregating up to ₹30,000 million₹30.00k Cr
- achieve the benefits of listing the Equity Shares on the Stock Exchanges
Risks the company discloses
A downturn or reduction in demand in either the Global Generics or Global CDMO business verticals could adversely affect the business, results of operations, cash flows and financial condition.(Revenue Concentration)
Revenue from the Global Generics business vertical may be adversely affected by increased price erosion resulting from a greater number of ANDA approvals for competing generic products.(Revenue Concentration)
Revenue from the Global Generics business vertical may be adversely affected by regulatory actions by the USFDA, including Official Action Indicated, warning letters, import alerts or facility-level enforcement actions.(Regulatory)
Revenue from the Global Generics business vertical may be adversely affected by changes in U.S. federal or state drug pricing legislation or reimbursement policies.(Regulatory)
Revenue from the Global CDMO business vertical may be adversely affected by the loss of or reduction in orders from customers.(Revenue Concentration)
Revenue from the Global CDMO business vertical may be adversely affected by delays or failures in technology transfer for new product mandates.(Operational)
Revenue from the Global CDMO business vertical may be adversely affected by underutilization of manufacturing capacity or capacity constraints.(Operational)
Revenue from the Global CDMO business vertical may be adversely affected by regulatory non-compliance at our manufacturing facilities that could result in the loss of customer contracts.(Regulatory)